UCB SA (EUR)
UCB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range88.58 | 91.00
52-Wk Range62.26 | 93.08
Last Close89.62
Mkt Cap (m)16,900.81
Dividend yield1.35%
ISINBE0003739530
Volume420,718
Exchange VenueBRU

Company Profile

UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.

Key Information
Price/Earning21.24
Price/Book2.40
Price/Sales3.42
P/CF19.02
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Annual Report
en 31/12/2019

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)3,3443,8764,1784,5304,632-
Operating Income (m)3686389211,1151,104-
Net Income (m)209623520753800-
Basic EPS1.103.252.764.004.24-
Avg. Diluted Shares Outstanding (m)190192188188188-
Balance Sheet
EUR201420152016201720182019
Current Assets (m)2,5012,8382,3312,6772,950-
Non Current Assets (m)7,6478,1187,8817,2407,564-
Total Assets (m)10,14810,95610,2129,91710,514-
Current Liabilities (m)2,3363,0612,4181,9492,238-
Total Liabilities (m)------
Total Equity (m)5,0025,6725,5845,8136,310-
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)5122454279271,089-
Capital Expenditure (m)-161-146-138-209-341-
Figures are quoted in EUR unless stated otherwise
-
No change
89.62
Last Price